We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
-13.19%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.78B
AUM Growth
+$18.3M
(+0.66%)
Cap. Flow
+$443M
Cap. Flow
% of AUM
15.93%
Top 10 Holdings %
Top 10 Hldgs %
42.27%
Holding
179
New
61
Increased
32
Reduced
13
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$37.6M |
| 2 |
UnitedHealth
UNH
|
+$37.4M |
| 3 |
United Therapeutics
UTHR
|
+$29.3M |
| 4 |
Merck
MRK
|
+$27.6M |
| 5 |
Agilent Technologies
A
|
+$24.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$27.7M |
| 2 |
CELG
Celgene Corp
CELG
|
+$26.8M |
| 3 |
CTRX
CATAMARAN CORP COM STK (CDA)
CTRX
|
+$26.5M |
| 4 |
RCPT
RECEPTOS INC COM STK (DE)
RCPT
|
+$23.7M |
| 5 |
ACOR
Acorda Therapeutics
ACOR
|
+$22.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.09% |
| 2 | Real Estate | 3.47% |
| 3 | Financials | 1.31% |
| 4 | Technology | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Gilead Sciences
GILD
$163B
| $218M | 7.84% |
2,221,431
+141,700
| +7% | +$15.7M |
|
|
CELG
2
DELISTED
Celgene Corp
CELG
| $185M | 6.66% |
1,713,634
-215,600
| -11% | -$26.8M |
|
|
3
Biogen
BIIB
$30.7B
| $136M | 4.9% |
467,183
+113,950
| +32% | +$37.6M |
|
4
Vertex Pharmaceuticals
VRTX
$122B
| $105M | 3.78% |
1,009,903
+112,000
| +12% | +$14.4M |
|
|
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
| $99.6M | 3.58% |
636,805
+52,500
| +9% | +$9.58M |
|
6
Incyte
INCY
$24.9B
| $97.1M | 3.49% |
880,461
| – | – |
|
7
Johnson & Johnson
JNJ
$617B
| $87.8M | 3.16% |
940,988
+56,376
| +6% | +$5.45M |
|
|
AGN
8
DELISTED
Allergan plc
AGN
| $86.3M | 3.1% |
317,686
-26,000
| -8% | -$7.99M |
|
9
Viatris
VTRS
$20.7B
| $82M | 2.95% |
2,035,657
+198,652
| +11% | +$11.1M |
|
10
Teva Pharmaceuticals
TEVA
$41.2B
| $78.2M | 2.81% |
1,385,594
-2,000
| -0.1% | -$130K |
|
11
Regeneron Pharmaceuticals
REGN
$77.4B
| $71.8M | 2.58% |
154,266
-32,900
| -18% | -$17.7M |
|
12
Alkermes
ALKS
$8.39B
| $68.4M | 2.46% |
1,165,818
+130,348
| +13% | +$8.61M |
|
13
BioMarin Pharmaceuticals
BMRN
$11.7B
| $60.1M | 2.16% |
570,477
+35,500
| +7% | +$4.74M |
|
14
Pfizer
PFE
$142B
| $56.6M | 2.03% |
1,899,615
+172,909
| +10% | +$5.54M |
|
15
Illumina
ILMN
$31B
| $53M | 1.9% |
309,779
+73,708
| +31% | +$14.9M |
|
|
16
Amgen
AMGN
$209B
| $44.5M | 1.6% |
321,640
-175,640
| -35% | -$27.7M |
|
|
AET
17
DELISTED
Aetna Inc
AET
| $36.3M | 1.31% |
331,931
| – | – |
|
|
18
UnitedHealth
UNH
$383B
| $36.3M | 1.3% |
+312,600
| New | +$37.4M |
|
|
19
Merck
MRK
$321B
| $33.6M | 1.21% |
713,790
+519,910
| +268% | +$27.6M |
|
20
Bristol-Myers Squibb
BMY
$132B
| $31.7M | 1.14% |
535,240
| – | – |
|
|
AKRX
21
DELISTED
Akorn Inc
AKRX
| $24.2M | 0.87% |
849,482
| – | – |
|
|
22
United Therapeutics
UTHR
$26.2B
| $24M | 0.86% |
+182,600
| New | +$29.3M |
|
23
Molina Healthcare
MOH
$10.2B
| $24M | 0.86% |
347,901
| – | – |
|
|
MDCO
24
DELISTED
Medicines Co
MDCO
| $23.7M | 0.85% |
+624,300
| New | +$21.9M |
|
25
Humana
HUM
$44B
| $23.1M | 0.83% |
129,300
+17,300
| +15% | +$3.2M |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q3 2015 Portfolio in Review
As of Q3 2015, Tekla Capital Management held 179 positions worth $2.78B, up 0.66% from $2.76B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Tekla Capital Management deployed $443M of net new capital in Q3 2015, opening 61 new positions and adding to 32 existing holdings. Its largest new stake was UnitedHealth: 312,600 shares worth $36.3M.
By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 84% a quarter earlier, followed by Real Estate and Financials.
On the sell side, the largest reduction was Amgen, an estimated $27.7M trimmed.
- Tekla Capital Management's largest Q3 2015 buy was UnitedHealth: 312,600 shares worth $36.3M.
- Tekla Capital Management added most to Biogen in Q3 2015, an estimated $37.6M increase.
- Tekla Capital Management's biggest Q3 2015 reduction was Amgen, cutting an estimated $27.7M.
- Tekla Capital Management fully exited CATAMARAN CORP COM STK (CDA) in Q3 2015, selling an estimated $26.5M.
- Tekla Capital Management's ten largest holdings make up 42% of its $2.78B portfolio in Q3 2015.
- Tekla Capital Management opened 61 new positions and closed 19 in Q3 2015.
- Tekla Capital Management's portfolio value rose 0.66% quarter-over-quarter to $2.78B.
Based on Tekla Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.